Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate and compare the therapeutic effects on OAB symptoms, and sexual functions, in terms of erectile function and ejaculatory function, in sexually active OAB male treated with behavior therapy or behavior therapy plus Mirabegron (50 mg).


Clinical Trial Description

Overactive bladder (OAB) syndrome is a subset of storage-predominant lower urinary tract symptoms (LUTS) and has a significant impact on quality of life. Men with OAB generally experience a reduced quality of life, which may include a negative impact on sexual function. A previous study revealed that OAB is associated with erectile dysfunction (ED; prevalence odds ratio, 1.5; 95% confidence interval, 1.1-2.2) to a level comparable with that of hypertension or diabetes, both of which are known risk factors for ED. Furthermore, men with OAB were nine and seven times more likely to report diminished sexual enjoyment and decreased sexual activity, respectively, due to urinary symptoms than men without urinary symptoms. Behavior therapies are designed as first- line treatment for the treatment of OAB with or without concomitant medication. Mirabegron, a selective β3 adrenoceptor agonist, is indicated for the treatment of OAB. Earlier research studying the role and distribution of β3-adrenoreceptors revealed that the receptors exert other physiological functions such as lipolysis and are present not only in adipose tissue but also in human gall bladder, colon, prostate, skeletal muscles and corpus cavernosum (CC) smooth muscles. It was found that activation by a selective experimental β3-receptor agonist, BRL 37344, elicited relaxation of human CC smooth muscle via a cGMP-dependent but NO-independent mechanism, leading to observable β3-receptor-mediated vasorelaxant tone of CC. The potential effect of β3-receptor agonism at human CC mediated by highly selective mirabegron in both human CC and rat CC that mirabegron markedly relaxed isolated CC strips by activating β3-adrenoceptors localized in cavernosal smooth muscle cells, independently of the NO-cGMP pathway. Recently, intra-cavernosal injection of mirabegron improved erectile function and neurogenic relaxation of corpus cavernosum in diabetic rats. These early results have spurred research interest in mirabegron-induced CC relaxation and encouraged further clinical studies observing and evaluating the effect of mirabegron on male sexual function. Researchers at Johns Hopkins University has recently completed recruitment of a phase 1 interventional trial (NCT02916693) that aimed to address the hypothesis that activation of β3-adrenoceptors by mirabegron offers an alternative pharmacologic pathway for the treatment of erectile dysfunction. A preliminary small-scale prospective interventional study including 128 male LUTS patients treated with mirabegron 50 mg, 34 of whom had diagnosis of OAB and were sexually active, showed that mirabegron usage did not improve erectile function, as evaluated by International Index of Erectile Function (IIEF-5 4.9% decrease at 4-week; p = 0.106, and 9.1% decrease at 12-week follow-up; p = 0.077). However, the IIEF-5 was significantly decreased in the higher baseline IIEF-5 (≥17) group (11.7% decrease; p = 0.044), noncoronary artery disease (13.2%; p = 0.007) group and non-DM group (13.9% decrease; p = 0.021) at 12-week follow-up. The accumulated research output warrants the initiation of a prospective study involving a larger patient cohort to evaluate the effect of mirabegron on male sexual function in addition to alleviate OAB symptoms. The objective of this study is to evaluate and compare the therapeutic effects on OAB symptoms, and sexual functions, in terms of erectile function and ejaculatory function, in sexually active OAB male treated with behavior therapy or behavior therapy plus Mirabegron (50 mg). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04420533
Study type Interventional
Source Chang Gung Memorial Hospital
Contact
Status Completed
Phase N/A
Start date June 5, 2020
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Completed NCT02493647 - Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk N/A
Completed NCT03533192 - Replication of Evidence-based Programs N/A
Completed NCT02548871 - Evaluation of the Teen Outreach Program in Chicago Public Schools N/A
Completed NCT00220597 - Group Therapies for Reducing HIV-risk Behavior in Women Who Have Survived Childhood Sexual Abuse N/A
Recruiting NCT05620849 - Young Adult Education on Alcohol & Health N/A
Completed NCT04035694 - Evaluation Study of the Online High School Media Aware Program N/A
Completed NCT04070950 - Sexuality of Women With Pelvic Cancer
Completed NCT04079608 - Rigorous Evaluation of High School FLASH N/A
Completed NCT03366636 - Project Legacy Impact Evaluation Study N/A
Completed NCT02613039 - Oral Contraceptive Therapy and Sexuality Phase 4
Completed NCT02736214 - Reproductive Life Plan-based Counseling With Men N/A
Withdrawn NCT01169922 - HIV Prevention With Adolescents: Neurocognitive Deficits and Treatment Response N/A
Completed NCT00249496 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1 N/A
Completed NCT02993185 - Making Healthy Decisions: A Trial Evaluating the "Your Move" Teen Pregnancy-prevention Intervention N/A
Active, not recruiting NCT01088542 - The Community Youth Development Study: A Test of Communities That Care N/A
Completed NCT03330522 - Reducing HIV Risk in Urban Women: Soap Opera Videos on Video-Capable Cell Phones N/A
Completed NCT02530645 - Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults N/A
Completed NCT02866292 - The Pelvic Floor Muscles Strength and Sexual Function in Primigravid and Non-pregnant Nulliparous N/A
Completed NCT00109421 - Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females N/A
Recruiting NCT05140980 - Sexuality Education: Knowledge of Women Aged 18 to 25